Ireland· IE-PA-EU/1/20/1430/031-035
Rybelsus 25 mg tablets
A semaglutide product containing semaglutide, registered in Ireland by Novo Nordisk A/S. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Semaglutide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Semaglutide · ATC A10BJ06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of semaglutide costs, country by country.
Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Semaglutide · price per daily dose (10.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$430.99
- IT Italy$11.85
The record
At a glance
HPRA (Ireland)- Active substance
- Semaglutide
- Manufacturer
- Novo Nordisk A/S
- Country
- Ireland (IE)
- ATC code
- A10BJ06
- ATC class
- Semaglutide
- Defined daily dose
- 10.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/20/1430/031-035
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
301 interactions on record for semaglutide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Semaglutide · interactions on record
301 records
- 3 severe
- 258 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Semaglutide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYBELSUSNovo Nordisk A/S, Bagsvaerd
- United StatesWEGOVYNovo Nordisk Pharmaceutical Industries, LP
- NetherlandsRybelsus 25 mg tablettenNovo Nordisk A.S.
- FinlandRybelsusNovo Nordisk A/S
- PolandRybelsusNovo Nordisk A/S
- SwedenRybelsus 25 mg TablettNovo Nordisk A/S
- IcelandRybelsusNovo Nordisk A/S*
- SpainWEGOVY 25 MG COMPRIMIDOSNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kayshild, Ozempic
- Norway · Kayshild, Ozempic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/10d52322-d748-4027-854d-59de2d61aae8 GET /v1/drugs/10d52322-d748-4027-854d-59de2d61aae8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"A10BJ06"
],
"strength": null,
"pa_number": "EU/1/20/1430/031-035",
"substances": [
"Semaglutide"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "19/09/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about semaglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.